Cuorips Inc. (TYO:4894)

Japan flag Japan · Delayed Price · Currency is JPY
4,365.00
+15.00 (0.34%)
Jun 3, 2026, 3:30 PM JST
Market Cap35.92B -37.4%
Revenue (ttm)212.00M +21.1%
Net Income-1.02B
EPS-124.47
Shares Out 8.26M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume185,600
Open4,280.00
Previous Close4,350.00
Day's Range4,060.00 - 4,420.00
52-Week Range4,060.00 - 12,400.00
Beta0.82
Analystsn/a
Price Targetn/a
Earnings DateMay 15, 2026

About Cuorips

Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of human iPS cell-derived cardiomyocyte sheets. The company offers cellular and tissue-based, and cell processing products. It also provides contract development and manufacturing, and consulting services. The company was formerly known as Cuore Inc. and changed its name to Cuorips Inc. in June 2017. Cuorips Inc. was incorporated in 2017 and is headquartered in Tokyo, Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 56
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4894
Full Company Profile

Financial Performance

In fiscal year 2026, Cuorips's revenue was 212.00 million, an increase of 21.14% compared to the previous year's 175.00 million. Losses were -1.02 billion, 58.7% more than in 2025.

Financial Statements